# Mavacamten is approved, but target cannot be identified by OpenTargets **URL:** \ **Category:** Community Feedback\ **Tags:** genetics-portal\ **Created:** [2 May 2022 22:49 UTC](https://community.opentargets.org/t/mavacamten-is-approved-but-target-cannot-be-identified-by-opentargets/568 "2022-05-02T22:49:37Z")\ **Posts on this page:** 2\ **Page:** 1
**Author:** ![Shicheng\_Guo](https://dub1.discourse-cdn.com/flex017/user_avatar/community.opentargets.org/shicheng_guo/32/217_2.png) [@Shicheng\_Guo](https://community.opentargets.org/u/Shicheng_Guo)\ **Post date:** [2 May 2022 22:49 UTC](https://community.opentargets.org/t/mavacamten-is-approved-but-target-cannot-be-identified-by-opentargets/568/1 "2022-05-02T22:49:37Z")
Dear Team, Mavacamten is approved, but neither target nor Mechanisms of Action cannot be identified by OpenTargets. Any optimization can be done? 4 days ago — Camzyos™ ( _mavacamten_ ) is the first and only cardiac myosin inhibitor approved by the U.S. Food and Drug Administration (FDA) indicated for the … [https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-new-drug-improve-heart-function-adults-rare-heart-condition](https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-new-drug-improve-heart-function-adults-rare-heart-condition) Thanks Shicheng ---
**Author:** ![JarrodBaker](https://dub1.discourse-cdn.com/flex017/user_avatar/community.opentargets.org/jarrodbaker/32/44_2.png) [@JarrodBaker](https://community.opentargets.org/u/JarrodBaker)\ **Post date:** [3 May 2022 12:59 UTC](https://community.opentargets.org/t/mavacamten-is-approved-but-target-cannot-be-identified-by-opentargets/568/2 "2022-05-03T12:59:22Z")
Hi Shicheng [Here](https://platform.opentargets.org/drug/CHEMBL4297517) is the Mevacamten page from the Open Targets platform. Our mechanism of action data is taken from [ChEMBL](https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4297517/). Once they have include further information it will flow through to the platform. Cheers Jarrod